1-3 of 3
Stephen B. Heitner
Close
Sort by
Journal Articles

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Rajshekhar Chakraborty, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D Cohen, Eric Rohren, Stephen B. Heitner, Kevin R. Kelly, Niklas J Mackler, David M. Baer, Antje Hoering, Brian G.M. Durie, Sikander Ailawadhi, Robert Z. Orlowski
Journal: Blood
Blood (2022) 140 (Supplement 1): 4349–4351.
https://doi.org/10.1182/blood-2022-166609
Published: 2022
Journal Articles

Autologous Stem Cell Transplant in the Era of Bortezomib-Based Induction for AL Amyloidosis Results in Improved Hematologic Response Rates: a Single Institution 11 Year Experience

Carlton D. Scharman, MD, Joseph J. Shatzel, MD, Richard T. Maziarz, MD, Eva Medvedova, MD, Alex Stentz, MPH, Gloria Rhyne, MA, Chafic Karam, MD, Rupali S. Avasare, MD, Stephen B. Heitner, MD, Emma C. Scott, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4552.
https://doi.org/10.1182/blood.V130.Suppl_1.4552.4552
Published: 2017
Journal Articles

Does Increased Body Mass Index Predispose Myeloma Patients to Fractures or Shortened Survival?.

Emma C. Scott, MD, Alan L. Friedman, MD, Stephen B. Heitner, MD, Damian Silbermins, MD
Journal: Blood
Blood (2005) 106 (11): 5051.
https://doi.org/10.1182/blood.V106.11.5051.5051
Published: 2005